OBJECTIVE:

To determine the effects of the administration of 50 mg of DHEA orally daily on sexual function of menopausal patients.

MATERIALS AND METHODS:

We performed an experimental, clinical, prospective and longitudinal study in menopausal patients. We selected the sample from april to july 2017 with menopausal patients who attended for the first time at the clinic who met the inclusion criteria, having a final sample of 29 patients. Patients with a complete study protocol who met the entry criteria were administered 50 mg of prasterone (Biolaif™) orally daily for 12 months, with a follow-up consultation every 3 months. Descriptive statistics were used for the statistical analysis. Also, Friedman’s two-dimensional analysis was used. All statistical studies were conducted in the SPSS program, v.22.

RESULTS:

Sexual Function Index evaluated with 29 patients at 6 months increased from an average of 10.8 to 28.1. At 12 months with 18 patients, after the treatment with 50 mg prasterone orally daily, it increased from an average of 10.6 to 29.1.

CONCLUSIONS:

Sexual dysfunction is an underdiagnosed health problem in patients over the postmenopausal stage. Administration of prasterone (DHEA) at a dose of 50 mg orally daily improved the domains of Female Sexual Function Index of all our patients with statistically significant results, without side effects of hyperandrogenism.